Today: 9 April 2026
Subscribe
Browse Category

NYSE:RHHBY 17 July 2025 - 16 September 2025

Big Pharma’s Billion-Dollar Bet: Inside Eli Lilly’s $5B Virginia Factory and America’s New Drug Manufacturing Boom

Big Pharma’s Billion-Dollar Bet: Inside Eli Lilly’s $5B Virginia Factory and America’s New Drug Manufacturing Boom

Eli Lilly will invest $5 billion to build a 200,000-square-foot drug manufacturing plant in Goochland County, Virginia, creating 650 permanent jobs and 1,800 construction jobs. The facility will produce active pharmaceutical ingredients for cancer and autoimmune treatments. The project is part of Lilly’s $27 billion U.S. expansion plan. Virginia approved over $10 million in incentives to secure the site.
16 September 2025
·······
Biotech Breakthroughs, Pharma Power Moves & Health Shocks: News Roundup (Aug 18–19, 2025)

Biotech Breakthroughs, Pharma Power Moves & Health Shocks: News Roundup (Aug 18–19, 2025)

Genentech is ending its $2 billion cell therapy partnership with Adaptive Biotechnologies, citing cost-cutting but no safety issues. Kriya Therapeutics raised $313 million in Series D funding, one of the year’s largest biotech rounds. The FDA delayed Neurizon’s ALS drug trial review until October due to staffing shortages. Stealth BioTherapeutics has resubmitted its elamipretide application for Barth syndrome after two FDA rejections.
19 August 2025
····
AI Pathology Breakthrough: Roche’s Lung Cancer Diagnostic Makes FDA History

AI Pathology Breakthrough: Roche’s Lung Cancer Diagnostic Makes FDA History

Roche’s Ventana TROP2 (EPR20043) RxDx test became the first AI-powered diagnostic to receive FDA Breakthrough Device Designation in April 2025. The system uses digital pathology and AI to classify NSCLC tumors as TROP2-positive or negative, guiding use of Datopotamab deruxtecan. In a retrospective analysis, TROP2-positive patients saw a 43% lower risk of progression or death with the drug versus chemotherapy.
17 July 2025
·

Stock Market Today

  • Anterix (ATEX) Gains as Bull of the Day with Positive Earnings Surprises and Upward Estimates
    April 9, 2026, 8:47 AM EDT. Anterix (ATEX), focused on private wireless networks for critical infrastructure, especially U.S. electric utilities, stands as Zacks Rank #2 (Buy). Despite low Value and Growth grades, it beat earnings estimates four consecutive times, with an average surprise of 36%. Its latest quarterly loss was 35 cents per share versus an expected 57 cents, marking a 38.6% positive surprise. Analysts have revised earnings estimates upward for fiscal 2026, from $3.06 to $3.30 over 90 days, and slightly improved fiscal 2027 loss forecasts. The company's focus on Private LTE technology and reliable communication infrastructure is attracting market attention amid shifting wireless needs.

Latest article

When Will Gas Prices Fall? Iran Ceasefire May Not Bring Quick Relief as Oil Rebounds

When Will Gas Prices Fall? Iran Ceasefire May Not Bring Quick Relief as Oil Rebounds

9 April 2026
Brent crude rebounded 3% Thursday despite a U.S.-Iran ceasefire, with the Strait of Hormuz still nearly shut and only one oil-products tanker passing in 24 hours. U.S. gasoline averaged $4.166 a gallon on April 9, and AAA said prices could drop slowly. North Sea Forties crude hit a record $146.43 a barrel. The U.S. EIA expects Hormuz flows may take months to recover.
CoreWeave Stock Climbs on $21 Billion Meta AI Cloud Deal, but Debt Risks Stay in Focus

CoreWeave Stock Climbs on $21 Billion Meta AI Cloud Deal, but Debt Risks Stay in Focus

9 April 2026
CoreWeave said Meta Platforms committed about $21 billion for AI cloud capacity through December 2032. Shares rose 4.3% to $88.90 in premarket trading after the announcement. The deal follows an $8.5 billion loan facility and a $1.25 billion senior notes offering. CoreWeave reported $5.13 billion in 2025 revenue and ended December with a $66.8 billion backlog.
NVIDIA’s Rubin AI Chip Ramp Hits Fresh Snag as HBM4 Memory Crunch Clouds 2026

NVIDIA’s Rubin AI Chip Ramp Hits Fresh Snag as HBM4 Memory Crunch Clouds 2026

9 April 2026
TrendForce said April 8 that Nvidia’s Rubin AI chip shipments may be delayed by HBM4 memory qualification and cooling demands, shifting over 70% of 2026 high-end GPU volume to the current Blackwell line. Rubin’s projected share dropped to 22%. Samsung began shipping HBM4 to Nvidia in February, but SK Hynix and Micron face qualification delays. Broadcom signed a long-term deal to develop Google’s TPUs through 2031.
Go toTop